🧬 Endocrinology Update: Weekly Growth Hormone Approved, New T1D Subtype, AI Finds Hidden Risk and More
From AI-driven diabetes detection to new drug approvals and innovative therapies, we’ve got the must-know updates shaping the future of metabolic and hormonal health.
📌 In This Episode:
💉 FDA approves once-weekly SKYTROFA for adult growth hormone deficiency, improving adherence.
🌍 A non-autoimmune subtype of Type 1 Diabetes has been identified in African youth.
🏥 Singapore uses wrist fractures in older adults to successfully screen and treat osteoporosis.
💊 Crinetics’ oral acromegaly therapy PALSONIFY nears FDA approval after strong Phase 3 results.
🧠 Inflammation biomarkers may help predict depression treatment outcomes in diabetics.
⚖️ Amgen’s Maridebart Cafraglutide shows weight loss promise in non-diabetic Phase 3 trial.
🤖 AI model uncovers hidden diabetes risk missed by traditional HbA1c testing.
🧓 AI-driven tools improve elderly diabetes care and cut hospitalizations by 25 percent.
🍬 One in five children with Type 1 Diabetes found to have undiagnosed liver disorders.
🧪 Korean firms push stem cell-based islet therapy for diabetes with early success in mice.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology, diabetes, thyroid health, and more.
#Endocrinology #DiabetesResearch #HormoneTherapy #MetabolicHealth #GrowthHormone #AIinHealthcare #Acromegaly #Type1Diabetes #ObesityTreatment #LiverHealth #StemCellTherapy #PrecisionMedicine #LucidQuest #HealthcareInnovation